The Precivity™ blood tests are tests that healthcare providers can order to aid in the diagnosis and treatment of Alzheimer’s disease.

The PrecivityAD2™ and PrecivityAD® blood tests determine whether a patient with signs or symptoms of memory decline or dementia has high or low likelihood of having changes in the brain that are associated with Alzheimer’s disease. Healthcare providers determine which Precivity™ test is right for their patient.

The PrecivityAD2™ and PrecivityAD® blood tests use highly sensitive and specialized laboratory technologies to identify and measure certain proteins that are found in the blood and that are known to be associated with presence of brain amyloid plaques, one of the brain pathology findings of Alzheimer’s disease. The main test result is a score that determines a patient’s likelihood category for presence of brain amyloid plaques. Like other tests that evaluate for brain amyloid pathology in clinical patients [such as amyloid PET scan or cerebrospinal fluid (CSF) testing] the Precivity™ blood tests by themselves do not diagnose Alzheimer’s disease. Healthcare providers interpret the test results along with other medical information.

If you are experiencing memory loss, you should talk to your healthcare provider. Your healthcare provider can determine if a Precivity™ blood test is right for you.

Only your healthcare provider can order a Precivity™ blood test. Please speak with your healthcare provider to understand whether a Precivity™ blood test is right for you.

Your healthcare provider will talk with you about which Precivity™ blood test is right for you.

A Precivity™ blood test may be appropriate for you if you are beginning to show signs or symptoms of memory loss – often called mild cognitive impairment (MCI), regardless of your family history. The National Institute on Aging lists the signs of MCI as:

• Losing things often,
• Forgetting to go to events or appointments, and
• Having more trouble coming up with words than other people of the same age

If you do not have a provider, you can reach out to your local Alzheimer’s Association to ask for a list of specialists near you. Unfortunately, C₂N Diagnostics is not able to recommend specific providers, but C₂N’s customer service and laboratory staff are happy to talk more with your healthcare provider about the Precivity™ blood tests. Your provider can call 1-877-C2N-DIAG(226-3424) to learn more.

After your healthcare provider orders the test, a medical professional will collect a small amount of blood from a vein in your forearm using a standard collection vial. Your blood test sample will be sent to C₂N’s laboratory for analysis.

You do not need to fast or stop taking your medications before your blood collection for the Precivity™ blood tests.

The Precivity™ tests are new and are not currently covered by private insurance payers, Medicare or Medicaid. Until each commercial and Medicare Advantage plan issues a positive coverage statement we will not know if the test will be covered by that plan. Commercial and Medicare Advantage plans may still pay for the test on a case-by-case basis without a formal coverage policy if the plan chooses to do so. In the event a commercial or Medicare Advantage plan does not pay for the test, we will still pursue payment from the insurer.

C₂N offers a financial assistance program to those that medically and financially qualify. Information about the program and how to apply are on our website at Cost & Billing. You have up to 30 days after you receive your first bill to complete the application. Please call 1-877-C2N-DIAG (226-3424) for more information.

You will receive a bill in the mail after your medical claim has been sent to your healthcare provider. A financial assistance program is available for those patients that medically and financially qualify. A six-month, interest-free payment plan is also available to facilitate access to the Precivity™ tests. Please follow the instructions on the bill to make a payment. C₂N accepts major credit cards and personal checks. You may make a payment online on our secure portal at Patient Portal, mail, or over the phone. For billing related questions, please call 1-877-C2N-DIAG (226-3424) for more information.

A Precivity™ blood test report is sent to your healthcare provider as soon as your results are ready. Your healthcare provider will discuss your report with you, answer any questions, and discuss the next steps in your care and management.

The PrecivityAD2™ blood test or the PrecivityAD® blood test will tell your healthcare provider your likelihood for having changes in the brain associated with Alzheimer’s disease.

• The main test result of the PrecivityAD2™ blood test is a score called the Amyloid Probability Score 2 (APS2), which determines a patient’s likelihood (positive or negative) for presence of amyloid plaques in the brain.
  
• The main test result of the PrecivityAD® blood test is a score called the Amyloid Probability Score (APS), which determines a patient’s likelihood (Low, Intermediate, or High) for presence of amyloid plaques in the brain. The PrecivityAD® blood test also includes a patient’s APOE status.
  
• The Precivity-ApoE™ blood test reports a patient’s ApoE protein types (E2, E3, or E4) to determine APOE status which may be useful for decision-making about treatment options.
  

Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive issues serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. For more information and resources on Alzheimer’s disease, please visit Alzheimer's Association or visit our website at Benefits of an Early Diagnosis.